Financial Comparison
Cipla Limited vs Divi's Laboratories Limited
Click a ticker to view the full analysis.
In short
Divi's Laboratories Limited is the more profitable of the two, keeping 24.5% of revenue as net profit against 14.0% for Cipla Limited. Divi's Laboratories Limited trades at the higher trailing P/E (91.9× vs 39.0× for Cipla Limited), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for Cipla Limited and 1 for Divi's Laboratories Limited.
Based on filings for periods ending 31 Mar 2026 (CIPLA.NS) and 31 Mar 2026 (DIVISLAB.NS) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. CIPLA.NS shown solid · DIVISLAB.NS shown dashed. Not financial advice.
| Metric | CIPLA.NS | DIVISLAB.NS |
|---|---|---|
| Price | ₹1,397.10 | ₹10,097.00 |
| Market Cap | ₹1.13T | ₹2.68T |
| P/E (TTM) | 39.0x | 91.9x |
| P/B | 3.2x | 16.0x |
| Beta | 0.10 | 0.18 |
| Div Yield | 0.93% | 0.30% |
| Revenue (TTM) | ₹277.1B | ₹104.8B |
| Net Income | ₹38.8B | ₹25.7B |
| Gross Margin | 62.3% | 59.1% |
| Risk Flags | — | 2 flags |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.